Gracell Biotechnologies Inc ADR (NASDAQ: GRCL) stock jumped 5.11% on Friday to $4.94 against a previous-day closing price of $4.70. With 0.7 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.4 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $4.9900 whereas the lowest price it dropped to was $4.6500. The 52-week range on GRCL shows that it touched its highest point at $6.99 and its lowest point at $1.40 during that stretch. It currently has a 1-year price target of $11.71. Beta for the stock currently stands at -0.92.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of GRCL was up-trending over the past week, with a rise of 12.27%, but this was up by 78.99% over a month. Three-month performance surged to 55.35% while six-month performance rose 107.56%. The stock gained 34.60% in the past year, while it has gained 114.78% so far this year. A look at the trailing 12-month EPS for GRCL yields -1.02 with Next year EPS estimates of -0.20. For the next quarter, that number is -0.04. This implies an EPS growth rate of 17.55% for this year and 6.45% for next year.
Float and Shares Shorts:
At present, 95.93 million GRCL shares are outstanding with a float of 71.32 million shares on hand for trading. On Oct 30, 2023, short shares totaled 0.9 million, which was 1.32% higher than short shares on Sep 28, 2023. In addition to Dr. Wei Cao BM, Ph.D. as the firm’s Founder, Chairman & CEO, Dr. Yili Xie M.B.A., Ph.D. serves as its Chief Financial Officer.
Institutional Ownership:
Through their ownership of 52.90% of GRCL’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 32.02% of GRCL, in contrast to 1.53% held by mutual funds. As the largest shareholder in GRCL with 10.32% of the stake, Temasek Holdings Pte Ltd. holds 9,901,940 shares worth 9,901,940. A second-largest stockholder of GRCL, RA Capital Management LP, holds 8,333,333 shares, controlling over 8.69% of the firm’s shares. Logos Global Management LP is the third largest shareholder in GRCL, holding 2,525,000 shares or 2.63% stake. With a 0.79% stake in GRCL, the Biotech Growth Trust Plc is the largest stakeholder. A total of 756,304 shares are owned by the mutual fund manager. The iShares Biotechnology ETF, which owns about 0.40% of GRCL stock, is the second-largest Mutual Fund holder. It holds 381,681 shares valued at 1.28 million. BlackRock Event Driven Equity Fun holds 0.07% of the stake in GRCL, owning 64,671 shares worth 0.22 million.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for GRCL since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With GRCL analysts setting a high price target of $20.00 and a low target of $7.00, the average target price over the next 12 months is $11.71. Based on these targets, GRCL could surge 304.86% to reach the target high and rise by 41.7% to reach the target low. Reaching the average price target will result in a growth of 137.04% from current levels.
